About the Company
We do not have any company description for Outlook Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Outlook Therapeutics, Inc.
Outlook Therapeutics Increases Previously Announced Bought Deal ...
About Outlook Therapeutics, Inc. Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ...
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook ...
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outlook Therapeutics, Inc ...
Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal
Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351 (a) regulatory pathway, initially for wet AMD.
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 ...
ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...
OTLK - Outlook Therapeutics Inc Valuation | Morningstar
Review the current valuation for Outlook Therapeutics Inc (OTLK:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.
Outlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC ...
OUTLOOK THERAPEUTICS INC WKN: A4046T | ISIN: US69012T3059 | Ticker-Symbol: 41O Tradegate 16.07.25 | 19:10 ...
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Q3 2024 Earnings Call ...
Operator: Greetings. And welcome to the Outlook Therapeutics Corporate Third Quarter Fiscal Year 2024 Update Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Outlook Therapeutics, Inc.: Outlook Therapeutics Provides Update on ...
ISELIN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of ...
Is Outlook Therapeutics, Inc. (OTLK) A Good Stock To Buy?
Outlook Therapeutics, Inc. (NASDAQ: OTLK) shares haven't seen a lot of action during the first quarter. Overall, hedge fund sentiment was unchanged.
Similar Companies
Loading the latest forecasts...